Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pathology is alleviated by doxycycline in a laminin-alpha2-null model of congenital muscular dystrophy.

Annals of neurology - 1 Jan 2009

Girgenrath Mahasweta, Beermann Mary Lou, Vishnudas Vivek K, Homma Sachiko, Miller Jeffrey Boone

Abstract excerpt

OBJECTIVE: Congenital muscular dystrophy type 1A is an autosomal recessive disease that is caused by loss-of-function mutations in the laminin-alpha2 gene, and results in motor nerve and skeletal muscle dysfunction. In a previous study, we used genetic modifications to show that inappropriate ind...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CD11b Antigen
Share to Cell Line, Transformed
Share to Doxycycline

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to In Situ Nick-End Labeling

Share to Laminin

Share to Muscular Dystrophy, Animal

Share to Staurosporine

Share to Threonine

Source

Open in PubMed Open full text

Identifiers

PMID: 19086074
DOI: 10.1002/ana.21523
PMCID: PMC2639627

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19086074-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pathology is alleviated by doxycycline in a laminin-alpha2-null model of congenital muscular dystrophy.PMID 19086074Read ↗

Inhibition of apoptosis improves outcome in a model of congenital muscular dystrophy.Semantic proximity Read ↗

Laminin alpha2 chain-null mutant mice by targeted disruption of the Lama2 gene: a new model of merosin (laminin 2)-deficient congenital muscular dystrophy.Semantic proximity Read ↗

Transgenic overexpression of laminin α1 chain in laminin α2 chain–deficient mice rescues the disease throughout the lifespanSemantic proximity Read ↗

Laminin-111 Protein Therapy Reduces Muscle Pathology and Improves Viability of a Mouse Model of Merosin-Deficient Congenital Muscular DystrophySemantic proximity Read ↗

Laminin-α2 Chain-Deficient Congenital Muscular Dystrophy: Pathophysiology and Development of Treatment.Semantic proximity Read ↗

Current understanding and treatment of cardiac and skeletal muscle pathology in laminin-α2 chain-deficient congenital muscular dystrophySemantic proximity Read ↗

Triggering regeneration and tackling apoptosis: a combinatorial approach to treating congenital muscular dystrophy type 1 A.Semantic proximity Read ↗

Laminin-111 protein therapy after disease onset slows muscle disease in a mouse model of laminin-α2 related congenital muscular dystrophy.Semantic proximity Read ↗

Early skeletal muscle pathology and disease progress in the dy3K/dy3K mouse model of congenital muscular dystrophy with laminin α2 chain-deficiencySemantic proximity Read ↗

Laminin α1 chain improves laminin α2 chain deficient peripheral neuropathySemantic proximity Read ↗

Laminin-111 improves muscle repair in a mouse model of merosin-deficient congenital muscular dystrophySemantic proximity Read ↗

A Family of Laminin α2 Chain-Deficient Mouse Mutants: Advancing the Research on LAMA2-CMDSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.